EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Kuros Biosciences AG (0RHR) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Kuros Biosciences AG £7.06, price £18.45, upside -61.7%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Energy · GB · Home Switzerland · ISIN CH0325814116

KB Broad data Sep 24, 2026

Kuros Biosciences AG

0RHR · LSE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value £7.06 · Strongly overvalued (−61.7%)
!Quality 53/100
!Mixed Growth (revenue 5y +97.5 %/yr)
!Thin margins · 1.8% net margin (TTM)
!negative free cash flow
!Narrow moat 31/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£46.55 £1.28 Fair Value £7.06 Jun 2015 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range £1.28 – £46.55 · fair‑value band £6.32 – £7.52 · the £18.45 price screens above the £7.06 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio.

Show more

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Stock analysis

Kuros Biosciences AG (0RHR) currently trades at £18.45, while our model-based Fair Value estimate is £7.06, 61.7% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of £11.91 per share, and 0 of the 15 models we run sit above the £18.45 price.

Bear case: the Multiples group reads lowest at £4.39, and 15 of the 15 models stay below the price. Evidence for this calculation is high.

Scenario range: £6.32 (bear) to £7.52 (bull), the price of £18.45 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Energy sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kuros Biosciences AG reported revenue of £121M in FY2025 versus £13.8M in FY2021, a compound +72.1%/yr. Reported net income was £2.1M in FY2025.

Key figures

Market cap £275M · P/S ratio 1.88 · EPS (TTM) £−0.2300 · Net margin 1.7% · Return on equity 3.3% · Return on assets (EBIT) −6.3% · Operating margin 6.6% · Revenue (TTM) £146M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Energy peers we cover trades at −66% fair-value upside, at −62%, 0RHR screens cheaper than that median.

Fair Value models

Bear £6.32 Fair Value £7.06 Bull £7.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV £6.98 £7.67 £8.25 70
Owner Earnings £6.74 £11.91 £21.52 68
Residual Income £5.57 £5.29 £5.28 68
All 15 models by family
DCF Models
Owner Earnings £6.74 £11.91 £21.52 68
Earnings-Based
Graham-Dodd £1.75 £12.24 £17.17 61
Lynch FV £6.32 £9.03 £11.74 59
PEG = 1.0 £6.32 £9.03 £11.74 55
EPV £6.98 £7.67 £8.25 70
Multiples
P/E Multiple £2.71 £3.61 £4.52 63
P/S Multiple £3.29 £4.39 £5.48 58
P/B Multiple £3.29 £4.39 £5.48 55
EV/EBIT £8.60 £10.83 £13.07 63
EV/EBITDA £7.46 £9.31 £11.16 64
EV/Revenue £10.03 £13.51 £16.99 52
Asset-Based
NCAV (Graham) £4.08 £5.46 £8.15 51
Economic Profit
Residual Income £5.57 £5.29 £5.28 68
ROIC Compounder £6.98 £7.67 £8.40 68
Growth Earnings
Growth-Adj P/E £7.41 £10.59 £13.76 65

Open the full fair value analysis →

Notify me when 0RHR reaches fair value

Put 0RHR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 53 · Market factors (momentum, volatility) 25

Profitability 51
Margins and returns on capital today
Quality Growth 87
Are margins and returns improving?
Cashflow 12
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 89
Disciplined investing over empire-building
Low Volatility 55
Calm price path (market factor)
Momentum 17
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 5
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+60.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+88.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+97.5%
Start year 2020 (pandemic)
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−289.3% (2020) → 6.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

0RHR screens overvalued: fair value 62% below the price. Compare with Reliance Industries Limited →

Compare Kuros Biosciences AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Oil & gas

Similar stocks

10 more Oil & Gas Refining & Marketing stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Reliance Industries Limited RELIANCE ₹1,168 ₹865.31 −26%
Valero Energy Corporation VLO $389.57 $131.30 −66%
Marathon Petroleum Corporation MPC $389.44 $109.88 −72%
Phillips 66 PSX $253.55 $86.65 −66%
Neste Oyj NESTE €31.47 €5.85 −81%
Formosa Petrochemical Corporation 6505 87.20 TWD 20.61 TWD −76%
Indian Oil Corporation IOC ₹135.70 ₹417.35 +208%
HF Sinclair Corporation DINO $106.19 $52.92 −50%
SK Innovation Co 096770 149,200 KRW 50,661 KRW −66%
Sunoco LP, SUN $74.76 $53.89 −28%

Explore undervalued stocks

More undervalued Energy stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kuros Biosciences AG · Fair Value
£7.06 −62%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Kuros Biosciences AG Fair Value". https://www.fairvalue-calculator.com/stock/0RHR

Frequently asked questions

Is Kuros Biosciences AG (0RHR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of £7.06 versus a price of £18.45, about −62% upside (overvalued).
What is the fair value of 0RHR?
Our model-based fair value for Kuros Biosciences AG is £7.06 (as of Sep 24, 2026), built from audited fundamentals. The current price: £18.45.
What is the quality score of 0RHR?
Kuros Biosciences AG has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kuros Biosciences AG (0RHR)?
Our model-based price target is the fair value of £7.06 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario £6.32, optimistic scenario £7.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Kuros Biosciences AG stock forecast for 2026?
Our models put fair value at £7.06, about −62% upside versus a price of £18.45 (overvalued). Cautious scenario £6.32, optimistic scenario £7.52. The calculation is refreshed regularly with new filings.
What is the revenue of Kuros Biosciences AG (0RHR)?
Kuros Biosciences AG reported trailing-twelve-month revenue of about £146M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Kuros Biosciences AG (0RHR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kuros Biosciences AG it is £7.06 per share (as of Sep 24, 2026), against a price of £18.45. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Kuros Biosciences AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0RHR trades above its calculated fair value: price £18.45, fair value £7.06, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RHR?
No. The price is what the market pays today (£18.45); the fair value is what the company's own numbers justify (£7.06). For Kuros Biosciences AG the two are £11.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kuros Biosciences AG worth?
The market values Kuros Biosciences AG at about £275M (market capitalisation, as of Sep 24, 2026). Per share that is £18.45; our models calculate a fair value of £7.06 per share.
What do the bullish and bearish scenarios say about 0RHR?
Our models span a range for Kuros Biosciences AG: cautious scenario £6.32, base £7.06, optimistic £7.52 per share (as of Sep 24, 2026, price £18.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0RHR from its 52-week high?
Kuros Biosciences AG trades at £18.45, about 44% below its 52-week high of £33.12 and 9% above the low of £16.88 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of £7.06 is for.
Which stocks are comparable to Kuros Biosciences AG?
From the same area (Energy) we also value Reliance Industries Limited, Valero Energy Corporation, Marathon Petroleum Corporation, Phillips 66, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kuros Biosciences AG stock attractive at the current price?
The data as of Sep 24, 2026: price £18.45, calculated fair value £7.06 (−62%), Quality Score 53/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RHR calculated?
We run Kuros Biosciences AG through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £7.06, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Kuros Biosciences AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kuros Biosciences AG (0RHR)?
The closing price on Oct 2, 2026 was £18.45. Our model-based fair value is £7.06, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kuros Biosciences AG right now?
The price sits above even our optimistic bull case (£7.52). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Kuros Biosciences AG

How large is the market capitalisation of Kuros Biosciences AG (0RHR)?
The market capitalisation of Kuros Biosciences AG is £275M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kuros Biosciences AG (0RHR)?
The price-to-sales ratio of Kuros Biosciences AG is 1.88 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kuros Biosciences AG (0RHR)?
Earnings per share at Kuros Biosciences AG are £−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Kuros Biosciences AG (0RHR)?
The net margin of Kuros Biosciences AG is 1.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kuros Biosciences AG (0RHR)?
The return on equity (ROE) of Kuros Biosciences AG is 3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kuros Biosciences AG (0RHR)?
On an EBIT basis the return on assets of Kuros Biosciences AG is −6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kuros Biosciences AG (0RHR)?
The operating margin of Kuros Biosciences AG is 6.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kuros Biosciences AG (0RHR)?
Revenue at Kuros Biosciences AG is growing +66.9% versus a year earlier (3y avg +88.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Kuros Biosciences AG (0RHR) generate?
The free cash flow of Kuros Biosciences AG is −£2.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kuros Biosciences AG (0RHR) hold?
Kuros Biosciences AG holds more cash than debt, £11.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.